Takeda Strengthens Its CAR-T Platform With GammaDelta Therapeutics Acquisition

Takeda Pharmaceuticals is expanding its off-the-shelf CAR-T cell program yet again, with the acquisition of GammaDelta Therapeutics, a company researching the unique abilities of gamma delta T-lymphocytes to attack blood cancers and solid tumors.
Source: Drug Industry Daily